Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
ConditionPancreatic Adenocarcinoma Metastatic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut Paoli-Calmettes
About this trial
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.
Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age > 18 years
Signed written informed consent specific to the PROMETAP study
Affiliation with a social security system
Treatment and follow-up performed at the Institut Paoli-Calmettes
Disqualifiers
None
Trial population
The study population will include adult men and women (≥18 years) diagnosed with metastatic pancreatic adenocarcinom
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Biopsy collection
Other interventionTumor cells isolation
Blood collection
Other interventionIsolation of blood monocytes
Treatment groups
64 Participants
are divided into 3 treatment groupsGroup A: Groupe 1-Initial2 interventions
Group B: Group 2- Relapse2 interventions
Group C: Group 3- Biological1 intervention
Trial outcomes
Primary outcomes
1
Evaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma
* Assessment of stromal dependency mechanisms; * Characterization and comparison of the metabolic profiles of primary pancreatic tumors and associated liver and lung metastases. These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response.
Time frame
From sample collection to completion of analyses, estimated at 3 yearsSecondary outcomes
1
Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma.
* Identification of prognostic markers of therapeutic response originating from the tumor microenvironment. * Identification of mechanisms of resistance to anti-tumor treatments linked to the microenvironment. * Identification of new therapeutic strategies capable of specifically targeting the tumor microenvironment.
Time frame
From sample collection to completion of analyses, estimated at 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov